Hyperuricemia is a biomarker of early mortality in patients with chronic obstructive pulmonary disease

Figures & data

Table 1 Clinical characteristics of patients in the retrospective study

Factors	Hyperuricemia	Normouricemia	P-value
Subjects (n)	34	68
Age, n (%)
<65 years	15 (44.1%)	31 (45.6%)	0.88
≥65 years	19 (55.9%)	37 (54.4%)
Sex, n (%)
Female	15 (44.1%)	30 (44.1%)	0.88
Male	19 (55.9%)	38 (55.9%)
Current smokers, n (%)
No	22 (64.7%)	41 (60.3%)	0.65
Yes	12 (35.3%)	27 (39.7%)
Diabetes, n (%)
No	5 (14.7%)	18 (26.5%)	0.18
Yes	29 (85.3%)	50 (73.5%)
GOLD stages, n (%)
I/II	17 (50.0%)	37 (54.4%)	0.67
III/IV	17 (50.0%)	31 (45.6%)
Death within 1 year, n (%)	5 (14.7%)	4 (5.9%)	0.15

Abbreviation: GOLD, Global Initiative for Chronic Obstructive Lung Disease.

Table 2 Univariate and multivariate Cox regression analysis evaluating the effect of hyperuricemia and confounders on mortality

	Univariate analysis		Multivariate analysis
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age (≥65 years)	1.13 (0.52–2.44)	0.32
Sex (female)	1.33 (0.61–2.90)	0.48
Smoking	1.15 (0.53–2.48)	0.72
Diabetes	2.00 (0.90–4.45)	0.089	1.75 (0.66–4.67)	0.262
GOLD stage (III/IV)	3.02 (1.32–6.91)	0.009	2.41 (0.95–6.15)	0.065
Hyperuricemia	2.29 (1.07–4.88)	0.032	2.68 (1.18–6.09)	0.019

Abbreviations: HR, hazard ratio; GOLD, Global Initiative for Chronic Obstructive Lung Disease; CI, confidence interval.

Figure 1 Kaplan–Meier survival curve assessing the influence of hyperuricemia on mortality in patients with COPD.